Biotech Analysts, along with Dr. Murray Stein, Professor at the University of California, discuss Neuphoria’s near-term Phase 3 AFFIRM-1 data in social anxiety disorder (SAD) with BNC210 on an Analyst/Industry conference call to be held on October 6 at 3 pm. Webcast Link
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEUP:
- Neuphoria Therapeutics: Strong Cash Position and Promising Pipeline Drive Buy Rating
- Neuphoria Therapeutics price target raised to $35 from $18 at Maxim
- Neuphoria Therapeutics completes target enrollment in Phase 3 AFFIRM-1 trial
- Neuphoria Therapeutics initiated with a Buy at Lucid Capital
- Neuphoria Therapeutics’s BNC210: Buy Rating Affirmed Ahead of Pivotal Phase 3 AFFIRM-1 Trial